Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies

Sun Jin Kim, Zhong Yao, Morgan C. Marsh, Debra M. Eckert, Michael S. Kay, Anna Lyakisheva, Maria Pasic, Aiyush Bansal, Chaim Birnboim, Prabhat Jha, Yannick Galipeau, Marc-André Langlois, Julio C. Delgado, Marc G. Elgort, Robert A. Campbell, Elizabeth A. Middleton, Igor Stagljar () and Shawn C. Owen ()
Additional contact information
Sun Jin Kim: University of Utah
Zhong Yao: University of Toronto
Morgan C. Marsh: University of Utah
Debra M. Eckert: University of Utah School of Medicine
Michael S. Kay: University of Utah School of Medicine
Anna Lyakisheva: University of Toronto
Maria Pasic: University of Toronto
Aiyush Bansal: University of Toronto
Chaim Birnboim: University of Toronto
Prabhat Jha: University of Toronto
Yannick Galipeau: University of Ottawa
Marc-André Langlois: University of Ottawa
Julio C. Delgado: ARUP Institute for Clinical and Experimental Pathology
Marc G. Elgort: ARUP Institute for Clinical and Experimental Pathology
Robert A. Campbell: University of Utah
Elizabeth A. Middleton: University of Utah
Igor Stagljar: University of Toronto
Shawn C. Owen: University of Utah

Nature Communications, 2022, vol. 13, issue 1, 1-9

Abstract: Abstract The COVID-19 pandemic triggered the development of numerous diagnostic tools to monitor infection and to determine immune response. Although assays to measure binding antibodies against SARS-CoV-2 are widely available, more specific tests measuring neutralization activities of antibodies are immediately needed to quantify the extent and duration of protection that results from infection or vaccination. We previously developed a ‘Serological Assay based on a Tri-part split-NanoLuc® (SATiN)’ to detect antibodies that bind to the spike (S) protein of SARS-CoV-2. Here, we expand on our previous work and describe a reconfigured version of the SATiN assay, called Neutralization SATiN (Neu-SATiN), which measures neutralization activity of antibodies directly from convalescent or vaccinated sera. The results obtained with our assay and other neutralization assays are comparable but with significantly shorter preparation and run time for Neu-SATiN. As the assay is modular, we further demonstrate that Neu-SATiN enables rapid assessment of the effectiveness of vaccines and level of protection against existing SARS-CoV-2 variants of concern and can therefore be readily adapted for emerging variants.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-31300-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31300-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-31300-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().